Cagrilintide

Cagrilintide is a long-acting, acylated analogue of amylin, a hormone co-secreted with insulin by pancreatic beta cells. It is engineered for stability and albumin binding to support once-weekly dosing, and it acts as a non-selective agonist across amylin and calcitonin receptors. Signalling in hindbrain and hypothalamic regions slows gastric emptying, suppresses postprandial glucagon and promotes satiety, reducing food intake. Because amylin and GLP-1 act through distinct but complementary appetite pathways, cagrilintide is studied both alone and combined with semaglutide ("CagriSema") to test whether the two mechanisms produce additive weight loss.

Cagrilintide is investigational and not approved for any use; evidence comes from phase 1b/2 trials. A phase 1b trial (Enebo et al., Lancet 2021) showed concomitant cagrilintide plus semaglutide 2.4 mg was well tolerated with an acceptable safety profile and greater weight loss than semaglutide alone. A 26-week dose-finding phase 2 monotherapy trial (Lau et al., Lancet 2021) in 706 adults reported dose-dependent weight loss, reaching roughly 10.8% at the 4.5 mg dose versus placebo. Larger phase 3 CagriSema programs are ongoing; long-term efficacy and safety are not yet established.

Educational overview only — no dosing instructions in the public hub.

The most frequently reported adverse effects in trials are gastrointestinal — nausea, vomiting, constipation and diarrhea — generally dose-dependent. Injection-site reactions have also been described. As an investigational agent, its long-term safety and rare-event profile are not established outside monitored clinical trials, and combination with semaglutide compounds GI tolerability concerns. Non-trial, 'research use only' material adds unquantified hazards: uncertain identity, dosing accuracy and purity, and no clinical supervision.

Cagrilintide is an experimental biologic with no approved formulation, so any consumer product falls outside pharmaceutical quality assurance. A third-party certificate of analysis documenting identity, purity and quantification (e.g., HPLC plus mass spectrometry) is the minimum verification — but it cannot replace the safety and efficacy evidence that only completed trials and regulatory review provide.

Investigational — in clinical trials (phase 2/3, including the CagriSema program) and not approved by the FDA, EMA or any other regulator for human use. It is not a licensed medicine; any sale for human consumption sits outside the approved framework and lacks quality assurance and medical supervision. Promising but unproven.